RxDoctor Payments Data

James Overlease, MD

Ophthalmology · Kansas City, MONPI 1154362077

Payments from drug & device makers

$2,980in general payments, 2019–2025

Across 155 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$448
  • Sight Sciences, Inc.$205
  • Bausch & Lomb Americas Inc.$178
  • Sun Pharmaceutical Industries Inc.$143
  • Mallinckrodt Hospital Products Inc.$139
  • plus $540 from 11 others

What the payments were for

  • Food & beverage$2,980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,980 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$407,490
Medicare patients
1,109
Services billed
3,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost160$86,387
RocklatanNetarsudil Mesylat/Latanoprost130$58,525
CombiganBrimonidine Tartrate/Timolol97$34,899
RestasisCyclosporine23$34,327
Latanoprost2,224$24,519
Alphagan PBrimonidine Tartrate72$23,717
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol82$17,034
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat799$14,606
Travoprost66$11,595
Brinzolamide53$9,635
VyzultaLatanoprostene Bunod27$9,530
SimbrinzaBrinzolamide/Brimonidine Tart26$7,587
Brimonidine Tartrate275$7,517
Prednisolone Acetate196$7,126
Timolol Maleate844$6,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,327$179,330352 claims
Aerie Pharmaceuticals, Inc.Rocklatan$129$58,525130 claims
Bausch & Lomb Americas Inc.Vyzulta$178$9,53027 claims
AlconSimbrinza$448$7,58726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →